Investigational drug · Phase 2
Dabogratinib
Also called: TYRA-300
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for FGFR3 Gene Mutation, FGFR3 Gene Alteration, Achondroplasia.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
1
Any phase or sponsor naming "Dabogratinib"
First trial start
2022
Nov 22, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Dabogratinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- FGFR3 Gene Mutation
- FGFR3 Gene Alteration
- Achondroplasia
- Low Grade Upper Tract Urothelial Carcinoma
- Locally Advanced Urothelial Carcinoma
- Metastatic Urothelial Carcinoma
- Solid Tumor
- Urothelial Carcinoma
- Solid Tumor, Adult
- Bladder Cancer
Approved drugs for the same conditions: Bladder and urothelial cancer · Achondroplasia · Oncology · Rare and genetic disease · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Dabogratinib" as an intervention, largest first.
- Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial CarcinomaPivotal-lookingRecruiting
Tyra Biosciences, IncIndustry
NCT07265947 · 285 participants (planned) · Start Dec 22, 2025 · Primary completion Oct 2030
Drug: Dabogratinib (TYRA-300) 60mg; Dabogratinib (TYRA-300) 80mg · For: Low Grade Upper Tract Urothelial Carcinoma
Sites: Loma Linda, California; Los Angeles, California; Tampa, Florida · 36 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Achondroplasia: From bone to bench to bedside an integrated review of medical and surgical management strategies.
Vásconez HC, Bacino CA · Growth Horm IGF Res 2026
- Systematic Analysis of Stromal-Epithelial Crosstalk Reveals the FGF21-FGFR3 Axis as a Key Driver of Corneal Wound Healing.
Zhu Z, Zhao H, Zhou Q, et al. · Invest Ophthalmol Vis Sci 2026
- Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity.
Starrett JH, Allen EL, Neal M, et al. · Mol Cancer Ther 2026
- Next-generation isoform-selective fibroblast growth factor receptor inhibitors.
Chen L · Trends Pharmacol Sci 2025
- Discovery of Potent FGFR2/3 Inhibitors to Overcome Mutation Resistance and Treat Achondroplasia.
Fu D, Han T, Yang Z, et al. · ACS Med Chem Lett 2025
- TYRA-300, an FGFR3-selective inhibitor, promotes bone growth in two FGFR3-driven models of chondrodysplasia.
Starrett JH, Lemoine C, Guillo M, et al. · JCI Insight 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.